date,title,source
Oct-23-18,Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033,GlobeNewswire
Nov-13-18,VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20,GlobeNewswire
